Last reviewed 2026-04-20 · How we verify

Dibenzheptropine (DEPTROPINE)

Phase 2 active Small molecule

Dibenzheptropine (generic name: DEPTROPINE) is a deptropine drug. It is currently in Phase 2 development.

Dibenzheptropine is thought to work by interacting with a specific molecular target, but the exact details of this interaction are not well understood.

Dibenzheptropine (DEPTROPINE) is a small molecule drug in the deptropine class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile, pharmacokinetics, and generic availability. Further research is needed to fully understand this compound. Its development history is also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DEPTROPINE
Drug class	deptropine
Target	Acetylcholine-binding protein, Soluble acetylcholine receptor
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and each lock has a specific key that fits perfectly. Dibenzheptropine is like a key that tries to fit into one of these locks, but we don't know which lock it's meant for or how well it fits.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dibenzheptropine CI brief — competitive landscape report
Dibenzheptropine updates RSS · CI watch RSS

Frequently asked questions about Dibenzheptropine

What is Dibenzheptropine?

Dibenzheptropine (DEPTROPINE) is a deptropine drug.

How does Dibenzheptropine work?

Dibenzheptropine is thought to work by interacting with a specific molecular target, but the exact details of this interaction are not well understood.

What is the generic name of Dibenzheptropine?

DEPTROPINE is the generic (nonproprietary) name of Dibenzheptropine.

What drug class is Dibenzheptropine in?

Dibenzheptropine belongs to the deptropine class. See all deptropine drugs at /class/deptropine.

What development phase is Dibenzheptropine in?

Dibenzheptropine is in Phase 2.

What does Dibenzheptropine target?

Dibenzheptropine targets Acetylcholine-binding protein, Soluble acetylcholine receptor and is a deptropine.

Drug class: All deptropine drugs
Target: All drugs targeting Acetylcholine-binding protein, Soluble acetylcholine receptor
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing